Investment Analysts’ Recent Ratings Updates for Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (NASDAQ: CPRX) has recently received a number of price target changes and ratings updates:

• 1/10/2025 – Catalyst Pharmaceuticals had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 1/9/2025 – Catalyst Pharmaceuticals had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
• 1/3/2025 – Catalyst Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 12/24/2024 – Catalyst Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 11/18/2024 – Catalyst Pharmaceuticals is now covered by analysts at Stephens. They set an “overweight” rating and a $35.00 price target on the stock.
• 11/11/2024 – Catalyst Pharmaceuticals had its price target raised by analysts at Truist Financial Co. from $30.00 to $36.00. They now have a “buy” rating on the stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded down $0.70 during trading hours on Friday, reaching $22.10. 510,870 shares of the stock were exchanged, compared to its average volume of 1,294,804. The stock’s fifty day simple moving average is $21.75 and its 200 day simple moving average is $19.88. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.12 and a 52 week high of $24.27.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last 90 days. 11.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Pacer Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 130,918.8% during the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after purchasing an additional 287,300 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Integral Health Asset Management LLC purchased a new position in Catalyst Pharmaceuticals during the second quarter worth about $4,260,000. Finally, Dimensional Fund Advisors LP grew its position in Catalyst Pharmaceuticals by 9.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.